NASDAQ:HARP Harpoon Therapeutics (HARP) Stock Forecast, Price & News $0.80 +0.12 (+17.65%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$0.67▼$0.8450-Day Range$0.55▼$0.8252-Week Range$0.54▼$3.35Volume691,453 shsAverage Volume154,188 shsMarket Capitalization$25.69 millionP/E RatioN/ADividend YieldN/APrice Target$4.71 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Harpoon Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside489.3% Upside$4.71 Price TargetShort InterestHealthy1.72% of Float Sold ShortDividend StrengthN/ASustainability-0.61Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$10 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.11) to ($0.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.76 out of 5 starsMedical Sector51st out of 983 stocksBiological Products, Except Diagnostic Industry6th out of 164 stocks 3.4 Analyst's Opinion Consensus RatingHarpoon Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.71, Harpoon Therapeutics has a forecasted upside of 489.3% from its current price of $0.80.Amount of Analyst CoverageHarpoon Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.72% of the float of Harpoon Therapeutics has been sold short.Short Interest Ratio / Days to CoverHarpoon Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Harpoon Therapeutics has recently decreased by 45.13%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHarpoon Therapeutics does not currently pay a dividend.Dividend GrowthHarpoon Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHarpoon Therapeutics has received a 76.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Harpoon Therapeutics is -0.61. Previous Next 2.4 News and Social Media Coverage News SentimentHarpoon Therapeutics has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Harpoon Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for HARP on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harpoon Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,000,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.00% of the stock of Harpoon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.52% of the stock of Harpoon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Harpoon Therapeutics are expected to grow in the coming year, from ($1.11) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harpoon Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harpoon Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarpoon Therapeutics has a P/B Ratio of 40.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Harpoon Therapeutics (NASDAQ:HARP) StockHarpoon Therapeutics Inc. is a clinical-stage immunotherapy company at the forefront of revolutionizing cancer treatment and other diseases. The company is developing a novel T-cell engagers class to use the body's immune system to fight infection. Harpoon currently has several products in various stages of clinical trials, such as HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors and HPN217, which is in Phase I/II clinical trials for the treatment of multiple myeloma. Shares of Harpoon have skyrocketed following the release of data from its Phase 1 clinical trial for HPN217, a single-agent candidate for pretreated patients with relapsed/refractory multiple myeloma (RRMM). The data showed clinical activity and a "tolerable safety profile," with low-grade CRS observed in 29% of patients following the first or second doses of the drug and no incidents of "Grade 3 or higher CRS." Analysts have a consensus price target of $8.75 on the stock, suggesting over 85% upside potential. Harpoon has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products incorporating TriTAC platform technology and soluble T cell receptors. In addition, the company has a preclinical stage product, HPN601, for treating multiple solid tumor indications.Read More Receive HARP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HARP Stock News HeadlinesMay 28, 2023 | finance.yahoo.comAnalysts Just Shipped A Meaningful Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) EstimatesMay 25, 2023 | americanbankingnews.comHarpoon Therapeutics, Inc. (NASDAQ:HARP) Given Average Rating of "Moderate Buy" by BrokeragesJune 4, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 24, 2023 | americanbankingnews.comCritical Review: Harpoon Therapeutics (NASDAQ:HARP) versus Codiak BioSciences (NASDAQ:CDAK)May 17, 2023 | americanbankingnews.comEquities Analysts Issue Forecasts for Harpoon Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:HARP)May 17, 2023 | americanbankingnews.comHarpoon Therapeutics (NASDAQ:HARP) Given "Reiterates" Rating at 500.comMay 15, 2023 | msn.comHC Wainwright & Co. Reiterates Harpoon Therapeutics (HARP) Buy RecommendationMay 15, 2023 | markets.businessinsider.comSVB Securities Remains a Buy on Harpoon Therapeutics (HARP)June 4, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 13, 2023 | americanbankingnews.comHarpoon Therapeutics, Inc. (NASDAQ:HARP) Short Interest Up 115.5% in AprilMay 12, 2023 | finance.yahoo.comHarpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Lags Revenue EstimatesMay 11, 2023 | seekingalpha.comHarpoon Therapeutics GAAP EPS of -$0.31 beats by $0.08, revenue of $8.58M beats by $3.77MMay 9, 2023 | finance.yahoo.comChinook Therapeutics (KDNY) Reports Q1 Loss, Tops Revenue EstimatesApril 25, 2023 | americanbankingnews.comHarpoon Therapeutics, Inc. (NASDAQ:HARP) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 21, 2023 | seekingalpha.comHarpoon Therapeutics files $250M mixed shelf registrationApril 21, 2023 | msn.comUnusual Call Option Trade in Harpoon Therapeutics (HARP) Worth $2.50KApril 18, 2023 | marketwatch.comHarpoon Therapeutics Presents Data for New ProTriTAC(TM) Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023April 18, 2023 | finance.yahoo.comHarpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023April 17, 2023 | finance.yahoo.comHarpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023April 10, 2023 | finance.yahoo.comHarpoon Therapeutics to Participate in the Canaccord Horizons in Oncology ConferenceApril 6, 2023 | americanbankingnews.comCanaccord Genuity Group Trims Harpoon Therapeutics (NASDAQ:HARP) Target Price to $8.00April 4, 2023 | americanbankingnews.comHarpoon Therapeutics, Inc. (NASDAQ:HARP) to Post FY2023 Earnings of ($1.11) Per Share, Cantor Fitzgerald ForecastsApril 1, 2023 | finance.yahoo.comNews Flash: 8 Analysts Think Harpoon Therapeutics, Inc. (NASDAQ:HARP) Earnings Are Under ThreatApril 1, 2023 | americanbankingnews.comBrokers Issue Forecasts for Harpoon Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:HARP)March 31, 2023 | americanbankingnews.comHarpoon Therapeutics, Inc. (NASDAQ:HARP) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMarch 31, 2023 | americanbankingnews.comSVB Leerink Comments on Harpoon Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:HARP)March 31, 2023 | americanbankingnews.comHC Wainwright Analysts Increase Earnings Estimates for Harpoon Therapeutics, Inc. (NASDAQ:HARP)See More Headlines HARP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HARP Company Calendar Last Earnings5/11/2023Today6/04/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HARP CUSIPN/A CIK1708493 Webwww.harpoontx.com Phone(650) 443-7400FaxN/AEmployees99Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.71 High Stock Price Forecast$8.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+489.3%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,730,000.00 Net Margins-169.83% Pretax Margin-169.83% Return on Equity-473.13% Return on Assets-67.72% Debt Debt-to-Equity RatioN/A Current Ratio1.45 Quick Ratio1.45 Sales & Book Value Annual Sales$31.92 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book40.00Miscellaneous Outstanding Shares32,110,000Free Float27,932,000Market Cap$25.69 million OptionableNot Optionable Beta1.55 Key ExecutivesJulia Marie EastlandPresident, Chief Executive Officer & DirectorFrank J. LanzaChief Financial & Accounting OfficerHolger WescheChief Scientific OfficerLuke N. WalkerChief Medical OfficerChatan CharanSVP-Technical & Manufacturing OperationsKey CompetitorsEntera BioNASDAQ:ENTXAIM ImmunoTechNYSE:AIMInhibikase TherapeuticsNYSE:IKTSurrozenNASDAQ:SRZNCyclo TherapeuticsNASDAQ:CYTHView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPBought 33,830 shares on 5/16/2023Ownership: 0.168%Two Sigma Investments LPBought 57,080 shares on 5/15/2023Ownership: 0.152%BlackRock Inc.Sold 154,137 shares on 5/12/2023Ownership: 1.135%Renaissance Technologies LLCSold 136,554 shares on 5/12/2023Ownership: 0.522%Prudential Financial Inc.Bought 43,400 shares on 5/12/2023Ownership: 0.115%View All Insider TransactionsView All Institutional Transactions HARP Stock - Frequently Asked Questions Should I buy or sell Harpoon Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HARP shares. View HARP analyst ratings or view top-rated stocks. What is Harpoon Therapeutics' stock price forecast for 2023? 7 brokers have issued 1-year price targets for Harpoon Therapeutics' shares. Their HARP share price forecasts range from $1.50 to $8.00. On average, they expect the company's share price to reach $4.71 in the next year. This suggests a possible upside of 489.3% from the stock's current price. View analysts price targets for HARP or view top-rated stocks among Wall Street analysts. How have HARP shares performed in 2023? Harpoon Therapeutics' stock was trading at $0.7257 at the beginning of the year. Since then, HARP shares have increased by 10.2% and is now trading at $0.80. View the best growth stocks for 2023 here. Are investors shorting Harpoon Therapeutics? Harpoon Therapeutics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 417,700 shares, a decline of 45.1% from the April 30th total of 761,200 shares. Based on an average daily volume of 226,400 shares, the days-to-cover ratio is presently 1.8 days. Approximately 1.7% of the shares of the company are sold short. View Harpoon Therapeutics' Short Interest. When is Harpoon Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our HARP earnings forecast. How were Harpoon Therapeutics' earnings last quarter? Harpoon Therapeutics, Inc. (NASDAQ:HARP) posted its quarterly earnings results on Thursday, May, 11th. The company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.11. The business earned $8.58 million during the quarter, compared to analyst estimates of $8.81 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 473.13% and a negative net margin of 169.83%. What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO? 5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend. What other stocks do shareholders of Harpoon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD). When did Harpoon Therapeutics IPO? (HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers. What is Harpoon Therapeutics' stock symbol? Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP." Who are Harpoon Therapeutics' major shareholders? Harpoon Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.14%), Renaissance Technologies LLC (0.52%), Acadian Asset Management LLC (0.30%), Sequoia Financial Advisors LLC (0.27%), Bailard Inc. (0.17%) and Two Sigma Investments LP (0.15%). Insiders that own company stock include Ansbert Gadicke, Bioventures 2014 LP Mpm, Georgia Erbez, Holger Wesche, Impact Fund (Cayman) Oncology and Ronald Hunt. View institutional ownership trends. How do I buy shares of Harpoon Therapeutics? Shares of HARP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Harpoon Therapeutics' stock price today? One share of HARP stock can currently be purchased for approximately $0.80. How much money does Harpoon Therapeutics make? Harpoon Therapeutics (NASDAQ:HARP) has a market capitalization of $25.69 million and generates $31.92 million in revenue each year. The company earns $-67,730,000.00 in net income (profit) each year or ($1.74) on an earnings per share basis. How can I contact Harpoon Therapeutics? Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.harpoontx.com. The company can be reached via phone at (650) 443-7400 or via email at ir@harpoontx.com. This page (NASDAQ:HARP) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harpoon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.